RU2010120847A - Соединения индолина, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний - Google Patents
Соединения индолина, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний Download PDFInfo
- Publication number
- RU2010120847A RU2010120847A RU2010120847/04A RU2010120847A RU2010120847A RU 2010120847 A RU2010120847 A RU 2010120847A RU 2010120847/04 A RU2010120847/04 A RU 2010120847/04A RU 2010120847 A RU2010120847 A RU 2010120847A RU 2010120847 A RU2010120847 A RU 2010120847A
- Authority
- RU
- Russia
- Prior art keywords
- indol
- dihydro
- ethyl
- acetamide
- methoxy
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 10
- 230000002265 prevention Effects 0.000 title claims abstract 4
- 150000002476 indolines Chemical class 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 230000007170 pathology Effects 0.000 claims abstract 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract 5
- 206010022437 insomnia Diseases 0.000 claims abstract 5
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 208000019901 Anxiety disease Diseases 0.000 claims abstract 3
- -1 [2- (6-methoxy-2,3-dihydro-indol-1-yl) ethyl] cyclopropanecarboxamide Chemical compound 0.000 claims abstract 3
- 230000036506 anxiety Effects 0.000 claims abstract 3
- 210000002249 digestive system Anatomy 0.000 claims abstract 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 229940126601 medicinal product Drugs 0.000 claims abstract 3
- 208000012672 seasonal affective disease Diseases 0.000 claims abstract 3
- 208000019116 sleep disease Diseases 0.000 claims abstract 3
- PWBULZJYQSUOIV-UHFFFAOYSA-N 1-[2-[6-(3-phenylpropoxy)-2,3-dihydroindol-1-yl]ethyl]cyclopropane-1-carboxamide Chemical compound C1CC2=CC=C(OCCCC=3C=CC=CC=3)C=C2N1CCC1(C(=O)N)CC1 PWBULZJYQSUOIV-UHFFFAOYSA-N 0.000 claims abstract 2
- VGEGJTNFJKGJSG-UHFFFAOYSA-N 2,2,2-trifluoro-n-[2-(6-methoxy-2,3-dihydroindol-1-yl)ethyl]acetamide Chemical compound COC1=CC=C2CCN(CCNC(=O)C(F)(F)F)C2=C1 VGEGJTNFJKGJSG-UHFFFAOYSA-N 0.000 claims abstract 2
- VUEUYLMHINPZCP-UHFFFAOYSA-N 2,2,2-trifluoro-n-[2-[6-(3-phenylpropoxy)-2,3-dihydroindol-1-yl]ethyl]acetamide Chemical compound C1=C2N(CCNC(=O)C(F)(F)F)CCC2=CC=C1OCCCC1=CC=CC=C1 VUEUYLMHINPZCP-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- HTQZTNCKIQGQLW-UHFFFAOYSA-N n-[2-(5-bromo-6-methoxy-2,3-dihydroindol-1-yl)ethyl]acetamide Chemical compound C1=C(Br)C(OC)=CC2=C1CCN2CCNC(C)=O HTQZTNCKIQGQLW-UHFFFAOYSA-N 0.000 claims abstract 2
- LRSCUDLZEOJNEN-UHFFFAOYSA-N n-[2-(6-methoxy-2,3-dihydroindol-1-yl)ethyl]acetamide Chemical compound COC1=CC=C2CCN(CCNC(C)=O)C2=C1 LRSCUDLZEOJNEN-UHFFFAOYSA-N 0.000 claims abstract 2
- SAUVZPBRAOWWHN-UHFFFAOYSA-N n-[2-(6-methoxy-2,3-dihydroindol-1-yl)ethyl]propanamide Chemical compound C1=C(OC)C=C2N(CCNC(=O)CC)CCC2=C1 SAUVZPBRAOWWHN-UHFFFAOYSA-N 0.000 claims abstract 2
- BTDOHXZTYNXNBL-UHFFFAOYSA-N n-[2-(6-methoxy-2,3-dihydroindol-1-yl)propyl]acetamide Chemical compound COC1=CC=C2CCN(C(C)CNC(C)=O)C2=C1 BTDOHXZTYNXNBL-UHFFFAOYSA-N 0.000 claims abstract 2
- DCNUJKSLBGXCCL-UHFFFAOYSA-N n-[2-(6-methoxy-3-methyl-2,3-dihydroindol-1-yl)ethyl]acetamide Chemical compound COC1=CC=C2C(C)CN(CCNC(C)=O)C2=C1 DCNUJKSLBGXCCL-UHFFFAOYSA-N 0.000 claims abstract 2
- BBCSQPHKBFZMRF-UHFFFAOYSA-N n-[2-(6-methoxy-5-phenyl-2,3-dihydroindol-1-yl)ethyl]acetamide Chemical compound COC1=CC=2N(CCNC(C)=O)CCC=2C=C1C1=CC=CC=C1 BBCSQPHKBFZMRF-UHFFFAOYSA-N 0.000 claims abstract 2
- KVBUIYXZHDWRSA-UHFFFAOYSA-N n-[2-(6-methoxy-5-pyridin-4-yl-2,3-dihydroindol-1-yl)ethyl]acetamide Chemical compound COC1=CC=2N(CCNC(C)=O)CCC=2C=C1C1=CC=NC=C1 KVBUIYXZHDWRSA-UHFFFAOYSA-N 0.000 claims abstract 2
- LIGFXOOCMXHVFZ-UHFFFAOYSA-N n-[2-[6-(2-phenylethoxy)-2,3-dihydroindol-1-yl]ethyl]acetamide Chemical compound C1=C2N(CCNC(=O)C)CCC2=CC=C1OCCC1=CC=CC=C1 LIGFXOOCMXHVFZ-UHFFFAOYSA-N 0.000 claims abstract 2
- NNMKLYXVTDXENJ-UHFFFAOYSA-N n-[2-[6-(2-phenylethoxy)-2,3-dihydroindol-1-yl]ethyl]propanamide Chemical compound C1=C2N(CCNC(=O)CC)CCC2=CC=C1OCCC1=CC=CC=C1 NNMKLYXVTDXENJ-UHFFFAOYSA-N 0.000 claims abstract 2
- TVOQLWJVRZIPPM-UHFFFAOYSA-N n-[2-[6-(3-phenylpropoxy)-2,3-dihydroindol-1-yl]ethyl]acetamide Chemical compound C1=C2N(CCNC(=O)C)CCC2=CC=C1OCCCC1=CC=CC=C1 TVOQLWJVRZIPPM-UHFFFAOYSA-N 0.000 claims abstract 2
- GXCQXEGURQQACG-UHFFFAOYSA-N n-[2-[6-(3-phenylpropoxy)-2,3-dihydroindol-1-yl]ethyl]butanamide Chemical compound C1=C2N(CCNC(=O)CCC)CCC2=CC=C1OCCCC1=CC=CC=C1 GXCQXEGURQQACG-UHFFFAOYSA-N 0.000 claims abstract 2
- HRDIWAMPNHYPTG-UHFFFAOYSA-N n-[2-[6-(3-phenylpropoxy)-2,3-dihydroindol-1-yl]ethyl]propanamide Chemical compound C1=C2N(CCNC(=O)CC)CCC2=CC=C1OCCCC1=CC=CC=C1 HRDIWAMPNHYPTG-UHFFFAOYSA-N 0.000 claims abstract 2
- SBYZSLNIQGCLLI-UHFFFAOYSA-N n-[2-[6-(4-phenylbutoxy)-2,3-dihydroindol-1-yl]ethyl]acetamide Chemical compound C1=C2N(CCNC(=O)C)CCC2=CC=C1OCCCCC1=CC=CC=C1 SBYZSLNIQGCLLI-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033664 Panic attack Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- FZIOCLNQSSZLEQ-UHFFFAOYSA-N 1-[2-[6-(2-phenylethoxy)-2,3-dihydroindol-1-yl]ethyl]cyclopropane-1-carboxamide Chemical compound C1CC2=CC=C(OCCC=3C=CC=CC=3)C=C2N1CCC1(C(=O)N)CC1 FZIOCLNQSSZLEQ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1. Соединения индолина, выбранные из группы, включающей ! N-[2-(6-метокси-2,3-дигидро-индол-1-ил)-этил]-ацетамид, ! N-[2-(6-метокси-2,3-дигидро-индол-1-ил)-этил]-пропионамид, ! [2-(6-метокси-2,3-дигидро-индол-1-ил)-этил]-циклопропанкарбоксамид, ! 2,2,2-трифтор-N-[2-(6-метокси-2,3-дигидро-индол-1-ил)-этил]-ацетамид, ! N-[2-(6-метокси-2,3-дигидро-индол-1-ил)-пропил]-ацетамид, ! N-[2-(3-метил-6-метокси-2,3-дигидро-индол-1-ил)-этил]-ацетамид, ! N-[2-(5-бром-6-метокси-2,3-дигидро-индол-1-ил)-этил]-ацетамид, ! N-[2-(6-метокси-5-пиридин-4-ил-2,3-дигидро-индол-1-ил)-этил]-ацетамид, ! N-[2-(6-метокси-5-фенил-2,3-дигидро-индол-1-ил)-этил]-ацетамид, ! N-[2-(6-фенетилокси-2,3-дигидро-индол-1-ил)-этил]-ацетамид, ! [2-(6-фенетилокси-2,3-дигидро-индол-1-ил)-этил]-циклопропанкарбоксамид, ! N-[2-(6-фенетилокси-2,3-дигидро-индол-1-ил)-этил]-пропионамид, ! N-{2-[6-(3-фенил-пропокси)-2,3-дигидро-индол-1-ил]-этил}-ацетамид, ! N-{2-[6-(3-фенил-пропокси)-2,3-дигидро-индол-1-ил]-этил}-бутирамид, ! N-{2-[6-(3-фенил-пропокси)-2,3-дигидро-индол-1-ил]-этил}-пропионамид, ! {2-[6-(3-фенил-пропокси)-2,3-дигидро-индол-1-ил]-этил}-циклопропанкарбоксамид, ! 2,2,2-трифтор-N-{2-[6-(3-фенил-пропокси)-2,3-дигидро-индол-1-ил]-этил}-ацетамид, ! N-{2-[6-(4-фенил-бутокси)-2,3-дигидро-индол-1-ил]-этил}-ацетамид и их фармацевтически приемлемые соли и гидраты. ! 2. Применение соединений по п.1 для изготовления лекарственного средства при лечении или профилактике мелатонинергических заболеваний. ! 3. Применение по п.2, в котором указанные мелатонинергические заболевания выбраны из группы, включающей депрессию, стресс, расстройства сна, тревожность, сезонные аффективные расстройства, кардиоваскулярные патологии, патологии пищеварительной системы, бессонницу или утомление, связанные со сменой часовых п�
Claims (7)
1. Соединения индолина, выбранные из группы, включающей
N-[2-(6-метокси-2,3-дигидро-индол-1-ил)-этил]-ацетамид,
N-[2-(6-метокси-2,3-дигидро-индол-1-ил)-этил]-пропионамид,
[2-(6-метокси-2,3-дигидро-индол-1-ил)-этил]-циклопропанкарбоксамид,
2,2,2-трифтор-N-[2-(6-метокси-2,3-дигидро-индол-1-ил)-этил]-ацетамид,
N-[2-(6-метокси-2,3-дигидро-индол-1-ил)-пропил]-ацетамид,
N-[2-(3-метил-6-метокси-2,3-дигидро-индол-1-ил)-этил]-ацетамид,
N-[2-(5-бром-6-метокси-2,3-дигидро-индол-1-ил)-этил]-ацетамид,
N-[2-(6-метокси-5-пиридин-4-ил-2,3-дигидро-индол-1-ил)-этил]-ацетамид,
N-[2-(6-метокси-5-фенил-2,3-дигидро-индол-1-ил)-этил]-ацетамид,
N-[2-(6-фенетилокси-2,3-дигидро-индол-1-ил)-этил]-ацетамид,
[2-(6-фенетилокси-2,3-дигидро-индол-1-ил)-этил]-циклопропанкарбоксамид,
N-[2-(6-фенетилокси-2,3-дигидро-индол-1-ил)-этил]-пропионамид,
N-{2-[6-(3-фенил-пропокси)-2,3-дигидро-индол-1-ил]-этил}-ацетамид,
N-{2-[6-(3-фенил-пропокси)-2,3-дигидро-индол-1-ил]-этил}-бутирамид,
N-{2-[6-(3-фенил-пропокси)-2,3-дигидро-индол-1-ил]-этил}-пропионамид,
{2-[6-(3-фенил-пропокси)-2,3-дигидро-индол-1-ил]-этил}-циклопропанкарбоксамид,
2,2,2-трифтор-N-{2-[6-(3-фенил-пропокси)-2,3-дигидро-индол-1-ил]-этил}-ацетамид,
N-{2-[6-(4-фенил-бутокси)-2,3-дигидро-индол-1-ил]-этил}-ацетамид и их фармацевтически приемлемые соли и гидраты.
2. Применение соединений по п.1 для изготовления лекарственного средства при лечении или профилактике мелатонинергических заболеваний.
3. Применение по п.2, в котором указанные мелатонинергические заболевания выбраны из группы, включающей депрессию, стресс, расстройства сна, тревожность, сезонные аффективные расстройства, кардиоваскулярные патологии, патологии пищеварительной системы, бессонницу или утомление, связанные со сменой часовых поясов, шизофрению, панические атаки, меланхолию, нарушения аппетита, ожирение, бессонницу, психотические заболевания, эпилепсию, болезнь Паркинсона, старческую деменцию, заболевания, связанные с нормальным или патологическим старением, мигрень, потерю памяти, болезнь Альцгеймера и нарушения мозгового кровообращения.
4. Фармацевтическая композиция, включающая соединения по п.1 и по меньшей мере фармацевтически приемлемый наполнитель.
5. Применение композиции по п.4 для изготовления лекарственного средства при лечении или профилактике мелатонинергических заболеваний.
6. Применение по п.5, в котором указанные мелатонинергические заболевания выбраны из группы, включающей депрессию, стресс, расстройства сна, тревожность, сезонные аффективные расстройства, кардиоваскулярные патологии, патологии пищеварительной системы, бессонницу или утомление, связанные со сменой часовых поясов, шизофрению, панические атаки, меланхолию, нарушения аппетита, ожирение, бессонницу, психотические заболевания, эпилепсию, болезнь Паркинсона, старческую деменцию, заболевания, связанные с нормальным или патологическим старением, мигрень, потерю памяти, болезнь Альцгеймера и нарушения мозгового кровообращения.
7. Способ лечения или профилактики мелатонинергических заболеваний, включающий введение пациенту эффективного количества по меньшей мере одного соединения по п.1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702798A ES2331274B1 (es) | 2007-10-25 | 2007-10-25 | Compuesto de indolina. |
| ESP200702798 | 2007-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010120847A true RU2010120847A (ru) | 2011-11-27 |
Family
ID=40219359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010120847/04A RU2010120847A (ru) | 2007-10-25 | 2008-10-23 | Соединения индолина, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110112148A1 (ru) |
| EP (1) | EP2203423A1 (ru) |
| JP (1) | JP2011500763A (ru) |
| KR (1) | KR20100075518A (ru) |
| CN (1) | CN101878200A (ru) |
| AR (1) | AR069003A1 (ru) |
| AU (1) | AU2008316472A1 (ru) |
| BR (1) | BRPI0818850A2 (ru) |
| CA (1) | CA2703453A1 (ru) |
| CL (1) | CL2008003139A1 (ru) |
| ES (1) | ES2331274B1 (ru) |
| MX (1) | MX2010004463A (ru) |
| RU (1) | RU2010120847A (ru) |
| TW (1) | TW200934760A (ru) |
| UY (1) | UY31423A1 (ru) |
| WO (1) | WO2009053440A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102942516B (zh) * | 2012-11-05 | 2015-02-25 | 宁波大学 | 一种生物碱类化合物及其制备方法和应用 |
| CN103044310B (zh) * | 2013-01-18 | 2015-02-04 | 贵阳医学院 | 二氢吲哚-3-乙酸衍生物、其制备方法以及在药物中的应用 |
| CN109071435A (zh) * | 2016-01-21 | 2018-12-21 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 吲哚啉衍生物、包含它们的组合物及其用途 |
| AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2680366B1 (fr) * | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9326192D0 (en) | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
| CA2186412A1 (en) * | 1995-10-31 | 1997-05-01 | Katherine S. Takaki | Ethylamino carbazole melatonergic agents |
-
2007
- 2007-10-25 ES ES200702798A patent/ES2331274B1/es not_active Withdrawn - After Issue
-
2008
- 2008-10-23 CN CN200880118151XA patent/CN101878200A/zh active Pending
- 2008-10-23 AR ARP080104617A patent/AR069003A1/es not_active Application Discontinuation
- 2008-10-23 RU RU2010120847/04A patent/RU2010120847A/ru not_active Application Discontinuation
- 2008-10-23 AU AU2008316472A patent/AU2008316472A1/en not_active Abandoned
- 2008-10-23 JP JP2010530462A patent/JP2011500763A/ja not_active Abandoned
- 2008-10-23 MX MX2010004463A patent/MX2010004463A/es active IP Right Grant
- 2008-10-23 KR KR1020107008669A patent/KR20100075518A/ko not_active Application Discontinuation
- 2008-10-23 US US12/739,666 patent/US20110112148A1/en not_active Abandoned
- 2008-10-23 BR BRPI0818850A patent/BRPI0818850A2/pt not_active IP Right Cessation
- 2008-10-23 CA CA2703453A patent/CA2703453A1/en not_active Abandoned
- 2008-10-23 WO PCT/EP2008/064389 patent/WO2009053440A1/en active Application Filing
- 2008-10-23 EP EP08842562A patent/EP2203423A1/en not_active Withdrawn
- 2008-10-24 CL CL2008003139A patent/CL2008003139A1/es unknown
- 2008-10-24 TW TW097140812A patent/TW200934760A/zh unknown
- 2008-10-24 UY UY31423A patent/UY31423A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011500763A (ja) | 2011-01-06 |
| WO2009053440A1 (en) | 2009-04-30 |
| ES2331274B1 (es) | 2010-10-21 |
| UY31423A1 (es) | 2009-04-30 |
| KR20100075518A (ko) | 2010-07-02 |
| ES2331274A1 (es) | 2009-12-28 |
| CL2008003139A1 (es) | 2009-03-06 |
| AU2008316472A1 (en) | 2009-04-30 |
| CA2703453A1 (en) | 2009-04-30 |
| AR069003A1 (es) | 2009-12-23 |
| TW200934760A (en) | 2009-08-16 |
| MX2010004463A (es) | 2010-05-03 |
| US20110112148A1 (en) | 2011-05-12 |
| BRPI0818850A2 (pt) | 2019-09-24 |
| EP2203423A1 (en) | 2010-07-07 |
| CN101878200A (zh) | 2010-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161672T1 (hr) | Novi kristalni oblik vi agomelatina, postupak priprave i farmaceutski pripravci istog | |
| AU2006203340B2 (en) | New crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| HRP20170095T1 (hr) | Novi kristalni oblik iii agomelatina, postupak za njegovu pripravu i farmaceutski pripravci istog | |
| JP4575337B2 (ja) | アゴメラチンの新規な結晶形態ｖ、その製造方法、およびそれを含有する薬学的組成物 | |
| CL2012001501A1 (es) | Co-cristal constituido por agomelatina y un acido organico que presenta un estado solido a temperatura ambiente; procedimientos de preparacion; composicion farmaceutica; y uso en el tratamiento de trastornos del sistema melatoninergico tales como estres, trastornos del sueño y trastornos de ansiedad generalizada, entre otros. | |
| US5591775A (en) | Trisubstituted naphthylalkylamides for disorders of the melatoninergic system | |
| CA2498152A1 (en) | Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | |
| MA30088B1 (fr) | Phenethylamines substituees possedant une activite serotoninergique et/ou norepinephrinergique | |
| WO2006027684A1 (en) | Therapeutic diphenyl ether ligands | |
| RU2010120847A (ru) | Соединения индолина, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний | |
| NZ601088A (en) | Alpha 4 beta 2 neuronal nicotinic acetylcholine receptor ligands | |
| TW200843727A (en) | Malonamides as orexin antagonists | |
| JP2010529130A5 (ru) | ||
| JP2011500763A5 (ru) | ||
| JP2011529477A5 (ru) | ||
| TW557291B (en) | Alfa-amino acid amides, preparation thereof and pharmaceutical composition containing the same | |
| WO2006105455A3 (en) | Methods of treatment utilizing certain melatonin derivatives | |
| HRP20090632T1 (hr) | Novi derivati naftalena, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
| JP2015521643A5 (ru) | ||
| RU2010120846A (ru) | Соединения 2,3-дигидробензофурана, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний | |
| CN1159316C (zh) | 异吲哚并吲哚酮化合物、它们的制备方法和含有它们的药物组合物 | |
| AR070003A1 (es) | Derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR070951A1 (es) | Compuestos de indano, sus usos para la preparacion de medicamentos y sus usos para el tratamiento de alteraciones melatoninergicas y composiciones farmaceuticas que los comprende | |
| RU2010120845A (ru) | Фенилпирролидиновые соединения, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний | |
| AR070004A1 (es) | Derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20121016 |